Allogeneic ABCB5⁺ mesenchymal stem cells for treatment-refractory chronic venous ulcers: a phase I/IIa clinical trial.

A separate analysis of the subjects with low (≤5%) wound size reduction or wound enlargement during screening showed median postbaseline reductions that were still highly significant at each postbaseline visit, although they were numerically smaller than in the FAS ( Figure 5 b).

also in 132,142 other papers